Hinova Pharmaceuticals’ HP518 Gains the US FDA’s Fast Track Designation to Treat Triple-Negative Breast Cancer (TNBC)
Shots:
- The US FDA has granted FTD to the company’s HP518 (oral PROTAC AR degrader that targets both wild-type AR & AR LBD mutants such as L702H) for treating AR+ triple-negative breast cancer (TNBC)
- HP518, in AR+ TNBC animal models, depicted favorable anti-tumor activity and a good safety profile. The company will provide updates on existing IND (IND 164902) for TNBC in the future
- In addition, HP518 is also being investigated for mCRPC under a P-I/II study across China with its P-I study across Australia showing various long-term PSA50 & partial responses plus favorable safety
Ref: Hinova Pharmaceuticals | Image: Hinova Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
